Introduction

Joint wear can affect movement and quality of life, causing pain and stiffness. This article looks at ChondroFiller, a non-surgical collagen injection used to support the joint, with realistic expectations throughout.

Why Joint Wear Is Hard to Manage

Cartilage allows the bones to glide smoothly and absorbs load, but it is notoriously slow to recover because it lacks a direct blood supply. Once worn, it does not readily heal, which is why options that support the joint are of interest.

What Is ChondroFiller?

ChondroFiller is a Class III CE-marked medical device: a collagen-based gel composed primarily of Type I collagen — the protein that forms much of our connective tissue. It is made by Meidrix Biomedicals in Germany and imported into the UK under prescription. The device is acellular (cell-free) and self-gels within approximately three to five minutes once placed, recruiting the patient's own progenitor cells to help restore the joint surface over time.

For joint wear, ChondroFiller is delivered by an ultrasound-guided outpatient injection into the joint, without removing healthy cartilage. This is the ChondroFiller injection pathway: non-surgical, no incision, and no general anaesthetic. The gel may settle over worn surfaces and add a protective, cushioning layer within the joint.

ChondroFiller Injection and Liquid Cartilage: Two Distinct Pathways

It is worth noting the difference between the ChondroFiller injection and Liquid Cartilage, as patients sometimes encounter both terms. The ChondroFiller injection — the subject of this article — is a non-surgical, outpatient procedure suited to accessible lesions and joint wear where theatre admission is not required.

Liquid Cartilage refers to a separate, surgical protocol developed at the London Cartilage Clinic by Professor Paul Y. F. Lee. It is a keyhole (arthroscopic) procedure that delivers the ChondroFiller scaffold together with biological adjuncts such as platelet-rich fibrin or plasma and, where indicated, the patient's own mesenchymal stem cells. Liquid Cartilage is surgery — it requires a theatre, anaesthesia, and a structured recovery — and is intended for larger or load-bearing defects. The two pathways are not synonyms; the right choice depends on individual assessment.

How the Injection May Help

By adding a protective collagen layer within the joint, ChondroFiller may help cushion the joint and reduce direct grinding between worn surfaces. Because it is collagen-based, it has biological potential — the scaffold attracts the body's own progenitor cells and may support the formation of new cartilage-like tissue over months to years. However, it is best understood as a supportive, joint-preserving injection, not a guaranteed repair, cure, or reversal of arthritis.

In published series, patients treated with ChondroFiller have shown meaningful improvements in function and pain scores over twelve to thirty-six months. Imaging via MOCART scoring in knee studies has reached around 80 and above, indicating good quality tissue fill at the repair site. Benefits vary between individuals and are not guaranteed.

The Patient Experience

ChondroFiller is a minimally invasive, ultrasound-guided injection — no open surgery is required. Afterwards, simple advice on activity and, where helpful, physiotherapy supports the best result. Most people return to normal activities promptly; benefits vary between people.

Conclusion

ChondroFiller injection offers a non-surgical way to add a supportive collagen layer within a worn joint, which may help cushion the joint and ease symptoms for some people. It is not a cure, and suitability depends on individual factors including the size and location of wear, overall joint health, and the patient's goals. For larger or more complex defects, the Liquid Cartilage surgical protocol may be more appropriate. At the London Cartilage Clinic, specialists can advise which pathway, if either, may be suitable for you.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.